XNCRHealthcare · BiotechnologyThe 14 Wall Street analysts covering Xencor, Inc. hold a median 12-month price target of $29 — +2.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 83 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Xencor, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (94): The shares have been drifting up relative to others.
Growth (34): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on XNCR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +2.5% from it.
Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Aug 2026 | Cantor Fitzgerald | Maintains | Overweight | $43 → $44 |
| 6 Aug 2026 | RBC Capital | Maintains | Outperform | $19 → $20 |
| 6 Aug 2026 | Wedbush | Maintains | Outperform | $26 → $30 |
| 30 July 2026 | Wedbush | Reiterates | Outperform | $26 |
| 7 July 2026 | Truist Securities | Maintains | Buy | $29 → $27 |
| 7 July 2026 | Truist Securities | Maintains | Buy | — |
| 11 May 2026 | JP Morgan | Maintains | Neutral | — |
| 24 Mar 2026 | JP Morgan | Downgrade | Neutral | — |
| 26 Feb 2026 | Barclays | Maintains | Overweight | — |
| 17 Dec 2025 | Barclays | Maintains | Overweight | — |
| 24 Nov 2025 | Truist Securities | Initiates | Buy | — |
| 6 Nov 2025 | Cantor Fitzgerald | Maintains | Overweight | — |
| 6 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 6 Nov 2025 | RBC Capital | Maintains | Outperform | — |
| 29 Oct 2025 | Barclays | Upgrade | Overweight | — |
| 27 Oct 2025 | RBC Capital | Maintains | Outperform | — |
| 6 Oct 2025 | Cantor Fitzgerald | Assumes | Overweight | $40 |
| 17 Sept 2025 | Barclays | Assumes | Underweight | $6.00 |
| 3 Sept 2025 | B of A Securities | Downgrade | Neutral | — |
| 2 Sept 2025 | Wedbush | Reiterates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. XNCR appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 10% of US stocks
Cheaper than 27% of US stocks
Cheaper than 83% of US stocks
Higher than 67% of US stocks
Higher than 56% of US stocks
Higher than 15% of US stocks
Higher than 3% of US stocks
Higher than 27% of US stocks
Higher than 21% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Xencor, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Xencor reported a second-quarter loss of $0.29 per share, which was narrower than the Zacks Consensus Estimate of a loss of $0.82 and the $0.41 per-share loss reported a year ago. The results beat revenue estimates.
Why it matters — A narrower-than-expected quarterly loss and revenue beat could signal improving financial performance for Xencor investors tracking the company's results.
Xencor reported its financial results for the second quarter ended June 30, 2026. President and CEO Bassil Dahiyat said the company is excited to present XmAb819 results at ESMO this fall along with other fast-approaching milestones across its wholly owned clinical pipeline.
Why it matters — The news highlights upcoming clinical data and pipeline milestones for Xencor's wholly owned programs, which are relevant events for XNCR shareholders to watch.
Xencor announced a Settlement Agreement with Alexion to resolve a commercial dispute related to U.S. royalties on Ultomoris (ravulizumab-cwvz). Under the agreement, Xencor will receive a payment from Alexion.
Why it matters — The resolution of this royalty dispute and the resulting payment provide clarity on a financial overhang for Xencor.
The 14 Wall Street analysts covering Xencor, Inc. have a median 12-month price target of $29, with estimates ranging from $14 to $44. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Xencor, Inc., 12 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xencor, Inc. 83 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Xencor, Inc. ranks 83 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (94 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +2.5% from the last close, and Ticker Nerd's factor model ranks Xencor, Inc. 83 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Xencor, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XNCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $44 over the next 12 months.
Xencor, Inc. returned +273.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Xencor Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibodies and antibody therapeutics.
The most recent item we track (Zacks Investment Research, 5 Aug 2026): "Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates". Xencor reported a second-quarter loss of $0.29 per share, which was narrower than the Zacks Consensus Estimate of a loss of $0.82 and the $0.41 per-share loss reported a year ago. The results beat revenue estimates.
Xencor Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibodies and antibody therapeutics. Powered by its proprietary XmAb protein engineering platform, Xencor designs drug candidates optimized for enhanced efficacy and safety profiles to treat patients with cancer, asthma, allergic diseases, and autoimmune conditions. The company maintains a broad pipeline, with more than 20 programs in clinical testing and numerous others in preclinical development. Notably, three XmAb medicines are currently marketed by strategic partners, enabling milestone payments, royalties, and collaborative advancements. Xencor focuses on expanding the therapeutic potential of antibodies through innovative protein engineering from the ground up, addressing severe diseases where conventional treatments fall short. Founded in 1997 and headquartered in Monrovia, California, Xencor plays a key role in the biotechnology sector by advancing next-generation biologics for unmet medical needs.
CEO Dr. Bassil I. Dahiyat Ph.D. · 260 employees · United States · https://www.xencor.com